



1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schwartz, et al.

Serial No.: 10/021,403

Filed: 12/12/2001

Group:

For: ADMINISTRATION OF NUCLEIC ACID SEQUENCE TO FEMALE
ANIMAL TO ENHANCE GROWTH IN OFFSPRING


RECEIVED

NOV 21 2003

TECH CENTER 1600/2900

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE
ACTION

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, which ever event occurs last 37 C.F.R. § 1.97(b).

Respectfully submitted,
JACKSON WALKER L.L.P.T. Ling Chwang
T. Ling Chwang
Registration No. 33,590November 11, 2003

Dated:

JACKSON WALKER L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/021,403
Filing Date	12/12/2001
First Named Inventor	Schwartz, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00031 (AVSI-0009)

U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

NOV 21 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as

indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 14 2003

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/021,403
Filing Date	12/12/2001
First Named Inventor	Schwartz, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00031 (AVSI-0009)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	BOHLEN, P., ESCH, F., BRAZEAU, P., LING, N., AND GUILLEMIN, R. (1983). Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. <i>Biochem. Biophys. Res. Commun.</i> 116, 726-734.	
	5	DRAGHIA-AKLI, R., FIOROTTO, M. L., HILL, L. A., MALONE, P. B., DEEVER, D. R., AND SCHWARTZ, R. J. (1999). Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. <i>Nat. Biotechnol.</i> 17, 1179-1183.	
	6	IRANMANESH A, SOUTH S, LIEM AY, CLEMMONS D, THORNER MO, WELTMAN A, VELDHUIS JD., "Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men." <i>Eur J Endocrinol.</i> 1998 Jul;139(1):59-71.	
	7	GONZALEZ L. ET AL., Up-regulation of GH-binding protein by mouse GH in transgenic mice overexpressing GH-releasing hormone. <i>Journal of endocrinology</i> , November 1999, vol 163, no. 2, pages 299-307.	
	8	KOVACS, M ET AL., Effects of antagonists of growth hormone-releasing hormone on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, and animal model of acromegaly. <i>Endocrinology</i> November 1997, Vol. 138, No 11, pages 4536-4542.	
	9	WOJTKIEWICZ PW, PHELPS CJ, HURLEY DLWORJTE, "Transcript abundance in mouse pituitaries with altered growth hormone expression quantified by reverse transcriptase polymerase chain reaction implicates transcription factor Zn-16 in gene regulation in vivo." <i>Endocrine.</i> 2002 Jun;18(1):67-74.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.